Posts

Posted on

Lument Finance Trust Announces Pricing of Public Offering of Series A Cumulative Redeemable Preferred Stock

PR Newswire

NEW YORK, April 29, 2021 /PRNewswire/ — Lument Finance Trust, Inc. (NYSE: LFT) (“LFT” or the “Company”) today announced that it priced an underwritten public offering of an aggregate of 2,400,000 shares of its newly designated 7.875% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”) at a public offering price of $25.00 per share, for net proceeds of approximately $58.1 million, after the underwriting discount but before estimated offering expenses payable by the Company. The offering is expected to close on May 5, 2021, subject to customary closing conditions.

The Company intends to use the net proceeds from this offering to make additional investments in target assets consistent with its investment strategy and for general corporate purposes.

LFT intends to file an application to list the Series A Preferred Stock on the New York Stock Exchange under the ticker symbol “LFTPrA.”

Piper Sandler and Raymond James are acting as joint book-running managers, and B. Riley Securities and JonesTrading are acting as co-managers for the offering.

A registration statement relating to these securities has been filed and declared effective with the Securities and Exchange Commission (the “SEC”).  This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering, when available, may be obtained from Piper Sandler & Co. at 1251 Avenue of the Americas, 6th Floor, New York, NY 10020, or by email at [email protected] or from Raymond James & Associates, Inc. at 880 Carillon Parkway, St. Petersburg, FL 33716, or by email at [email protected].

About LFT

LFT is a Maryland corporation focused on investing in, financing and managing a portfolio of commercial real estate debt investments.  The Company primarily invests in transitional floating rate commercial mortgage loans with an emphasis on middle-market multi-family assets.

LFT is externally managed and advised by OREC Investment Management, LLC d/b/a Lument Investment Management, a Delaware limited liability company.

The Company changed its name from Hunt Companies Finance Trust, Inc. to Lument Finance Trust, Inc., effective December 28, 2020.

Forward-Looking Statements

Certain statements included in this press release constitute forward-looking statements intended to qualify for the safe harbor contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act, as amended. For example, the fact that the offering has priced may imply that the offering will close, but the closing is subject to conditions customary in transactions of this type and may be delayed or may not occur at all. Forward-looking statements are subject to risks and uncertainties. You can identify forward-looking statements by use of words such as “believe,” “expect,” “anticipate,” “project,” “estimate,” “plan,” “continue,” “intend,” “should,” “may,” “will,” “seek,” “would,” “could,” or similar expressions or other comparable terms, or by discussions of strategy, plans or intentions. Forward-looking statements are based on the Company’s beliefs, assumptions and expectations of its future performance, taking into account all information currently available to the Company on the date of this press release or the date on which such statements are first made. Actual results may differ from expectations, estimates and projections. You are cautioned not to place undue reliance on forward-looking statements in this press release and should consider carefully the factors described in Part I, Item IA “Risk Factors” in the Company’s annual reports on Form 10-K, our quarterly reports on Form 10-Q, and other current or periodic filings with the SEC, when evaluating these forward-looking statements. Forward-looking statements are subject to substantial risks and uncertainties, many of which are difficult to predict and are generally beyond the Company’s control.  Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 pandemic. Additional information concerning these and other risk factors are contained in our 2020 10-K which is available on the SEC’s website at www.sec.gov. Except as required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Charles Duddy
Managing Director
(646) 248-0174
[email protected]

Media Contact:
Michael Ratliff
Director
(212) 588-2163
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lument-finance-trust-announces-pricing-of-public-offering-of-series-a-cumulative-redeemable-preferred-stock-301280261.html

SOURCE Lument Finance Trust, Inc.

Posted on

25madison Announces Closing of Latest Funding Round

Investors include Apollo Global Management and Endeavor

PR Newswire

NEW YORK, April 29, 2021 /PRNewswire/ — 25madison, a leading venture studio and incubator, today announced that it has closed on its latest funding round. Apollo Global Management, Inc. (NYSE: APO), the global alternative investment manager, Endeavor and a number of prominent high net worth individuals and family offices are among investors backing the venture studio’s focus on building early-stage companies.    

With $60 million of capital raised to date, 25madison is well positioned to execute on its mandate to build and invest in early stage companies.  Built by founders who have run successful companies, 25madison has generated early successes with its first incubations including harbor, an app making disaster preparedness easy and accessible; The Beet, an authoritative destination for plant-based living; and sparkling tequila beverage company Onda.

“We are delighted to announce this additional capital raise and our new strategic partnerships with both Apollo and Endeavor.  25madison builds businesses.  And we know that one of the most difficult challenges startups face is finding beta or distribution partners.  These new relationships, in particular our partnership with Apollo, provides both companies a tremendous opportunity to significantly lower execution risk while increasing the likelihood of market acceptance” said Steven Price, 25madison CEO.   

In its strategic partnership with Apollo, 25madison will help the investment firm and its portfolio companies anticipate disruption and create new revenue streams by partnering with, investing in, and co-incubating early-stage companies to accelerate growth.

David Sambur, Co-head of Private Equity at Apollo said, “We’re excited to work with 25madison. Apollo is well-known for its innovative approach to building better businesses and 25madison has successfully incubated and invested in early stage companies with deep operating engagement. Working together we can quickly identify synergistic partnerships, new revenue streams and early-stage investment opportunities for Apollo and our funds’ portfolio companies.” Aaron Sobel, a Partner in Apollo’s private equity group, has joined the 25madison Board of Directors.

Apollo funds have invested in a diverse array of innovative companies including ADT, Shutterfly, Tech Data, Rackspace Technology and Sun Country, one of the most successful IPO’s of 2021.  

Ben Enowitz, Senior Vice President, Corporate Development & Talent Ventures, Endeavor remarked, “We share 25madison’s vision for building next-gen businesses and look forward to continuing to identify opportunities for the clients we represent and the brands we own to forge meaningful partnerships with these new companies.”

The Apollo and Endeavor strategic partnerships are the latest step by 25madison to support building best-in-class start-up companies. In December, 25madison announced additions to its leadership team of Chair Michael Lynton, CEO Steven Price, President Matt-Fremont-Smith, and Chief Partnership Officer Kirk Posmantur including naming Justine Lee as COO, Matt Berberian as Head of Studio and Scott Brown as Head of User Experience. They are supported by a 15-person team with deep experience launching successful start-ups across industries.

“With this capital raise and our new partnerships, we are better positioned to execute on building breakthrough businesses and brands within our focused themes:  Enabling easier access to opportunity jobs; fintech and services for our growing senior population; modern wellness – from plant-based living to promoting better health in the home and workplace; and building next-gen B2B SaaS businesses,” says Price.

About 25madison: Founded in 2018, 25madison is a venture studio, incubating companies from the ground up and investing in early-stage companies from its offices in New York City, Miami, Atlanta, and Tel Aviv. For more, see www.25madison.com.

About Apollo: Apollo is a leading global alternative investment manager with offices in New York, Los Angeles, San Diego, Houston, Bethesda, London, Frankfurt, Madrid, Luxembourg, Mumbai, Delhi, Singapore, Hong Kong, Shanghai and Tokyo. Apollo had assets under management of approximately $455 billion as of December 31, 2020 in credit, private equity and real assets funds. For more information about Apollo, please visit www.apollo.com.

CONTACT

Margaret Strickland

25madison
917.808.4200
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/25madison-announces-closing-of-latest-funding-round-301280260.html

SOURCE 25madison

Posted on

SOL Global Provides Interim Unaudited Financials for the First Quarter Ended February 2021

SOL Global Provides Interim Unaudited Financials for the First Quarter Ended February 2021

SOL Global Reports Best Quarter Since its Inception

SOL Global Continues to Buy Back its Shares Under the Previously Announced Normal Course Issuer Bid

TORONTO–(BUSINESS WIRE)–
SOL Global Investments Corp. (“SOL Global” or the “Company“) (CSE: SOL) (OTCPK: SOLCF) (Frankfurt: 9SB) is pleased to provide its investors with unaudited financials for the first quarter ended February 28, 2021 and a general operational update concerning the Company’s assets and investments. All figures in this press release are in Canadian dollars, unless otherwise indicated.

Unaudited Quarter-End Results

  • For the quarter-ended February 28, 2021, the Company recorded a positive net income of $208 million VS quarter-end February 29, 2020 of $2.9 million. This represents a favourable change of $205.2 million.
  • Total gain from investments totalled $244 million for the quarter-ended February 28, 2021, compared to $2.6 million for the quarter-ended February 29, 2020. This represents a favourable change of $241.5 million between periods.
  • The Net Asset Value (“NAV”) per share is equal to $7.12 at February 28, 2021 VS $1.98 at February 29, 2020.
  • SOL Global has significantly strengthened its asset base as compared to previous quarters when market multiples were higher. The gains reported in the financial statements are reflective of material operational improvements and growth in the underlying investments. Core portfolio investments have either completed or entered into agreements to complete liquidity events that may unlock value for investors.

“I’m pumped for our stockholders and beyond proud of my team and partners for today’s results,” said SOL Global’s Chairman and CEO, Andy DeFrancesco. “Our year end results were strong, but we shattered expectations with this most recent quarter. Going forward, our sectors and holdings may change but our strategy, risk management and dedication to our stockholders will not.”

The Company’s financial statements for the quarter ended May 31, 2021 will be released on July 30, 2021

  • Forward looking guidance into the Company’s Q2 results:

    • Bluma Wellness Inc. (“Bluma”) was acquired by Cresco Labs Inc. (“Cresco Labs”) in an all stock transaction valued at USD$213 million.
    • The Company announced its intention to increase its ownership interest in Captor Capital (the parent company of One Plant California) to 15.7%.
    • The Company co-led Fyllo’s $30 million dollar Series B Financing, with a USD$4 million investment.
    • The Company made its first investment in the psychedelic sector, investing $2.6 million into Wesana Health.
    • The Company structured and led a recent financing into Green Scientific Labs, LLC (“GSL”), investing approximately $2.84 million for a 14.5% interest. The Company intends to increase its ownership in GSL by investing further into its RTO financing round, which is imminent.

Verano Operational Update

On March 31, 2021, Verano Holdings Corp. (“Verano”) announced it had entered into a definitive agreement to acquire all of the issued and outstanding equity interests of The Healing Center, LLC, adding three highly productive, award-winning dispensaries in the Pittsburgh-metro area.

On April 6,2021, Verano announced its full year results for the year ended December 31, 2020. Highlights include:

  • 2020 revenue of $355 million, growth of approximately 200%
  • Gross profit margin of 63% for full year 2020
  • 2020 net income of $245 million
  • 2020 adjusted EBITDA of $170 million, 48% margin

On April 22, 2021, Verano announced it had entered into definitive agreements for all of the issued and outstanding equity interests in Agri-Kind, LLC, Agronomed Holdings Inc. and Agronomed Biologics, LLC, which collectively will add the equity in two cultivation licenses (one active location plus another facility for additional cultivation and production that is currently under construction) and the equity in a permit to add six dispensaries (non-active, to be developed) in Pennsylvania. These equity transactions will enhance Verano’s presence in Pennsylvania and further the Company’s position as a U.S. market leader.

Bluma Wellness Operational Update

On April 14, 2021, Cresco Labs closed its acquisition of Bluma. As a result of the acquisition, Bluma is now a wholly-owned subsidiary of Cresco Labs.

On April 12, 2021, Cresco launched a new brand of branded gummies under the name Wonder Wellness Gummies.

On April 22, 2021, Cresco announced the appointment of Tarik Brooks to its board of directors and the retirement of Dominic Sergi.

Other Highlights for Q2

  • On March 15, 2021, the Company announced its first green tech investment in award-winning electric motorcycle company Damon Motorcycles (“Damon”). Damon recently raised USD$30 million after completing a bridge financing round led by SOL Global, Benevolent Capital Partners, LLC, Zirmania Investments Limited, and other investors. SOL Global invested CAD$6.1 million into Damon.
  • Update on Litigation with lender, 1235 Fund LP: As previously disclosed, the Company commenced litigation in New York against its lender seeking, among other relief, a declaration that the lender is only entitled to have a $50 million non-convertible debenture (the “Debenture”) repaid in cash, and not in Verano shares owned by the Company with a current market value of more than $350 million. Subsequently, the lender issued a claim against the Company and others in Ontario for repayment of the Debenture through Verano shares or in the alternative damages of not less than $550 million. The Company will be asking to stay the Ontario claim on the basis that the issues are already before the New York courts. The lender has asked that the proceedings in New York be stayed or dismissed, arguing that these matters should be decided by a court in Ontario.
  • As announced on March 2, 2021, the Company commenced a normal course issuer bid on April 1, 2021 (the “NCIB”). Under the NCIB, the Company may purchase up to 2,737,805 of the Company’s common shares (the “Common Shares”), representing approximately 5% of its issued and outstanding Common Shares on the date the NCIB was initiated. All Common Shares purchased under the NCIB will be purchased on the open market through the facilities of the Canadian Securities Exchange (the “CSE”) and will be at the prevailing CSE market price for the Common Shares at the time of purchase. Common Shares acquired by the Company under the NCIB are being purchased for cancellation.

COVID-19 Update

SOL Global and its investments and portfolio companies have continued to deliver for both clients and shareholders despite challenges in the overall cannabis space and uncertain market conditions caused by the ongoing COVID-19 pandemic. SOL Global’s portfolio companies and companies in which they retain a non-controlling economic interest, including Bluma have adapted to the current environment through the continued scale-up of existing Florida cannabis production facilities, the continued expansion of Bluma’s operating subsidiary, One Plant Florida’s, already robust home- and curbside-delivery network and online ordering system in Florida, and the continued oversight of strategic business opportunities. SOL Global remains confident that it will continue to weather the COVID-19 storm and will emerge from the pandemic as a strengthened leader in the larger cannabis marketplace.

About SOL Global Investments Corp.:

SOL Global is a diversified investment and private equity holding company engaged in the small and mid-cap sectors. The Company’s investment partnerships range from minority positions to large strategic holdings with active advisory mandates. The Company’s seven primary business segments include Retail, Agriculture, QSR & Hospitality, Media Technology & Gaming, and New Age Wellness.

Non-IFRS Financial Measures

This press release includes references to net asset value, which is a financial measure that does not have a standardized meaning prescribed by IFRS. Net asset value is calculated as the value of total assets less the value of total liabilities at a specific date. The Company believes this non-IFRS measure does not only provide management with comparable financial data for internal financial analysis but also provides meaningful supplemental information to investors. In particular, management believes this financial measure can provide information useful to its shareholders in understanding the performance of the Company and may assist in the evaluation of its business relative to that of its peers. Investors are cautioned that this non-IFRS measure should not be construed as an alternative to the measurements calculated in accordance with IFRS as, given the non-standardized meaning, it may not be comparable to similar measures presented by other issuers.

Cautionary Statements

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained in this press release includes, without limitation, , future operational plans of Verano, the completion of the transaction between Verano and The Healing Center, LLC, the completion of the transactions between Verano and Agri-Kind, LLC, Agronomed Holdings Inc. and Agronomed Biologics, LLC, the estimated impacts on the transactions on the business of Verano, future equity investments in Captor Capital, future plans in relation to litigation with 1235 Fund LP, purchases under the NCIB, and the Company’s expectations regarding its ability to operate and emerge from the COVID-19 pandemic.

Forward-looking information is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including the inability or failure of the Company’s portfolio companies to execute their business and strategic plans as contemplated or at all, the failure by Verano, The Healing Center, LLC, Agri-Kind, LLC, Agronomed Holdings Inc. and Agronomed Biologics, LLC to obtain all requisite corporate, regulatory and court approvals for the proposed transactions, the outcome of litigation in respect of the Debenture, changes in national or regional economic, legal, regulatory and competitive conditions and a resurgence in the COVID-19 pandemic.

Other risk factors include: the risks resulting from investing in the US marijuana industry, which may be legal under certain state and local laws but is currently illegal under U.S. federal law; the risks of investing in securities of private companies which may limit the Company’s ability to sell or otherwise liquidate those securities and realize value; reliance on management; the ability of the Company to service its debt; the Company’s ability to obtain additional financing from time to time to pursue its business objectives; competition; litigation; inconsistent public opinion and perception regarding the medical-use and adult-use marijuana industry; and regulatory or political change. Additional risk factors can also be found in the Company’s current MD&A, which has been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information.

The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

SOL Global Investments Corp.

Paul Kania, CFO

Phone: (212) 729-9208

Email: [email protected]

For media inquiries, please contact:

Davis Richardson

AMW PR

P: 212.542.3146

E: [email protected]

KEYWORDS: United States North America Canada New York Pennsylvania Florida

INDUSTRY KEYWORDS: Automotive Other Retail General Health Other Health Pharmaceutical Retail Electronic Games Other Professional Services Lodging Casino/Gaming Travel Entertainment Finance Fitness & Nutrition Professional Services Alternative Medicine Motorcycles Health Agriculture Alternative Vehicles/Fuels Natural Resources

MEDIA:

Posted on

FEMSA Announces First Quarter 2021 Results

MONTERREY, Mexico, April 29, 2021 (GLOBE NEWSWIRE) — Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA”) (NYSE: FMX; BMV: FEMSAUBD) announced today its operational and financial results for the first quarter of 2021.

ENHANCED DISCLOSURE

  • In a permanent effort to improve our disclosure to better match the evolution of our business and communicate our performance, we are making a change to the way we present our financial results:
    • Given the growing relevance and potential of our logistics and distribution business, we will report its results as a new segment going forward. With this addition, we will disclose our core operations as follows: i) FEMSA Comercio’s retail divisions: Proximity, Health and Fuel; ii) Logistics and Distribution; and iii) Coca-Cola FEMSA.
FINANCIAL SUMMARY FOR THE FIRST QUARTER 2021
Information includes figures in millions of Ps. and variations as change vs. same period last year
  Revenues   Gross Profit   Income

from Operations 		  Same-Store
Sales
                     
FEMSA CONSOLIDATED 124,474 1.8%   46,534 1.5%   9,525 0.1%    
FEMSA COMERCIO                    
Proximity Division 43,418 (4.8%)   17,374 (4.7%)   2,411 (21.1%)   (6.5%)
Health Division 17,750 16.0%   5,069 17.9%   810 110.4%   15.5%
Fuel Division (1) 8,535 (21.4%)   1,080 (21.3%)   208 (53.0%)   (22.4%)
LOGISTICS & DISTRIBUTION 10,809 N/A   2,353 N/A   367 N/A    
COCA-COLA FEMSA 44,690 (1.5%)   19,922 (3.8%)   5,899 3.0%    

(1)

variations vs. comparable results 		                 

Eduardo Padilla, FEMSA’s CEO, commented:

“The first quarter’s results show sequential improvement in most of our operations relative to the fourth quarter of 2020. Within the first quarter itself, we saw more encouraging data as the sequential improvement was also evident as the months went by in several markets, and the comparison base became less demanding. Having said that, the consumer environment remains challenging, and the health emergency remains serious as vaccination efforts are still incipient in most of our geographies. Therefore, directionally we are making progress, but we must remain vigilant, disciplined, and agile.

Furthermore, we continue to balance navigating our short-term challenges, with executing our long-term strategy. A good example of that is the sustainability-linked notes issuance we announced yesterday, that allowed us to tap the Euro market at record-low yields, helping us improve our debt maturity profile while reinforcing our commitment to ambitious ESG objectives for the next decade and beyond.”

Follow today´s event live
10:00 AM ET Earnings Conference Call

To obtain the full text of this earnings release, please visit our Investor Relations website at https://femsa.gcs-web.com/ under the Financial Reports section

FORWARD-LOOKING STATEMENTS

This report may contain certain forward-looking statements concerning our future performance that should be considered as good faith estimates made by us. These forward-looking statements reflect management’s expectations and are based upon currently available data. Actual results are subject to future events and uncertainties, which could materially impact our actual performance.

FEMSA is a company that creates economic and social value through companies and institutions and strives to be the best employer and neighbor to the communities in which it operates. It participates in the retail industry through FEMSA Comercio, comprising a Proximity Division operating OXXO, a small-format store chain, a Health Division, which includes drugstores and related activities, and a Fuel Division, which operates the OXXO Gas chain of retail service stations. In the beverage industry, it participates through Coca-Cola FEMSA, the largest franchise bottler of Coca-Cola products in the world by volume; and in the beer industry, as the second largest shareholder of Heineken, one of the world’s leading brewers with operations in over 70 countries. FEMSA also participates in the logistics and distribution industry through its Strategic Business Unit, which additionally provides point-of-sale refrigeration and plastic solutions to its business units and third-party clients. Across its business units, FEMSA has more than 320,000 employees in 13 countries. FEMSA is a member of the Dow Jones Sustainability MILA Pacific Alliance, the FTSE4Good Emerging Index and the Mexican Stock Exchange Sustainability Index, among other indexes that evaluate its sustainability performance. 



Media Contact
(52) 555-249-6843
[email protected]
www.femsa.com

Investor Contact
(52) 818-328-6167
[email protected]
www.femsa.com/inversionista

Posted on

Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — Daxor Corporation(NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in postural tachycardia syndrome (POTS) published in the Journal of the American College of Cardiology from the Vanderbilt Autonomic Dysfunction Center in Nashville, TN.

The study titled “Effect of High Dietary Sodium Intake in Patients with Postural Tachycardia Syndrome,” tested whether high sodium diet reduces orthostatic tachycardia (heart rate) and upright heart rate compared to low sodium diet in POTS patients and secondary, its effect on plasma volume and plasma norepinephrine. Blood volume parameters were measured with Daxor’s BVA-100 diagnostic blood test; a safe, accurate and objective means to directly quantify blood volume and composition. Blood volumes were expressed as a percent deviation from the patient’s ideal volumes.

The results showed that the mechanism of sodium intake directly affects intravascular blood volume as measured by the BVA-100 blood test. High dietary sodium compared to low dietary sodium increases plasma volume and decreases the heart rate supporting the recommendation to increase dietary sodium intake in POTS.

“This study shows the crucial need to identify and manage shifts in blood volume in order to guide optimal treatment and outcomes in POTS patients. Daxor’s BVA-100 blood test is the proven gold standard for doing so,” said Michael Feldschuh, CEO and President of Daxor Corporation. “Prior studies have shown marked heterogeneity in both total blood and red blood cell volume – both prevalent in POTS.”

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
[email protected]

 



Posted on

Marrone Bio Innovations to Report First Quarter 2021 Results on Thursday, May 13th at 4:30 p.m. Eastern Time

DAVIS, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2021, after market close on Thursday, May 13, 2021 at 4:30 p.m. Eastern time.

Management will host an investor conference call at 4:30 p.m. ET (1:30 p.m. PT) on May 13, 2021 to discuss Marrone Bio Innovations’ first quarter 2021 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information:

Q1 2021 Conference Call and Webcast

Date: Thursday, May 13, 2021
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
U.S. Dial-in: 1-866-248-8441
International Dial-in: 1-323-289-6576
Conference ID: 8735297
Webcast: http://public.viavid.com/index.php?id=144565

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

A playback of the call will be available through June 13, 2021. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 8735297. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: MBII Q1 2021 Webcast.

About
Marrone
Bio Innovations

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of more than 15 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of over 400 issued and pending patents. Its agricultural end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. MBII’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, sustainable solutions in agriculture.

Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.

Marrone
Bio Innovations Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.

Company Contact:

Clyde Montevirgen
Vice President of Business Development & Investor Relations
Telephone: 530-750-2800
[email protected]

Investor Relations Contact:

Lucas A. Zimmerman
Senior Vice President
MZ Group – MZ North America
Main: 949-259-4987
[email protected]
www.mzgroup.us

 



Posted on

Bright Mountain Media Puts the Spotlight on Alcohol Awareness Month in Helpful Series on LittleThings.com

LittleThings
initiative features
real life stories of alcohol use and dependency

Boca Raton, FL, April 29, 2021 (GLOBE NEWSWIRE) — Bright Mountain Media, Inc. (OTCQB: BMTM), an end-to-end digital media and advertising services platform, has launched a new series of articles on LittleThings.com to support the understanding of alcoholism during Alcohol Awareness Month.

“Every April the National Council for Alcoholism and Drug Dependence (NCADD) sponsors Alcohol Awareness Month to increase awareness and understanding of the causes and treatment of the nation’s #1 public health problem: alcoholism,” said Emily Smith, CEO of Wild Sky Media, a division of Bright Mountain Media. “In support of Alcohol Awareness Month, LittleThings is spotlighting some first-person real stories of when the Wine Mom trope actually becomes problematic. It’s become especially clear during the pandemic that the isolation of quarantine took a harsher toll on the day-to-day realities of motherhood than many of us care to admit. A May 2020 survey showed alcohol consumption increased 27% after the pandemic hit. And even more recently, alcohol-related liver disease among young women is spiking at an alarming rate. So many people, moms and non-moms alike, have realized that they’ve become reliant on alcohol in a way that doesn’t feel healthy and are probably drinking more than they’d like to. We hope this series reaches those who need it most.”

LittleThings
a
rticles
available for
Alcohol Awareness Month

About Bright Mountain Media

Bright Mountain Media, Inc. (OTCQB: BMTM) is an end-to-end digital media and advertising services platform, efficiently connecting brands with targeted consumer demographics through the removal of middlemen in the advertising services process. The Company’s publishing division, led by Wild Sky Media, offers significant global reach through hyper-engaging content and multicultural audiences, reaching over 230 million users monthly as it tells the unique stories of our most diverse generation. The Company’s robust portfolio of websites includes Mom.com, CafeMom, LittleThings, MamásLatinas and many more. For more information, please visit www.brightmountainmedia.com.

Forward-Looking Statements for Bright Mountain Media, Inc.

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes, ” and similar words. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to expectations of our ability to successfully integrate acquisitions., and the realization of any expected benefits from such acquisitions You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in Bright Mountain Media, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as filed with the Securities and Exchange Commission on May 14, 2020 and our other filings with the SEC. Bright Mountain Media, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor Contact:

Greg Falesnik or Luke Zimmerman
MZ Group – MZ North America
949-259-4987
[email protected]
www.mzgroup.us



Posted on

OSS to Host First Quarter 2021 Conference Call on Thursday, May 13, 2021 at 5:00 p.m. ET

ESCONDIDO, Calif., April 29, 2021 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (Nasdaq: OSS), a leader in specialized high-performance edge computing, will hold a conference call on Thursday, May 13, 2021 at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2021. The financial results will be issued in a press release prior to the call.

OSS management will host the conference call followed by a question-and-answer period.

Date: Thursday, May 13, 2021
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Toll-free dial-in number: 1-800-437-2398
International dial-in number: 1-786-204-3966
Conference ID: 9721579

The conference call will be webcast live and available for replay here as well as via a link in the Investors section of the company’s website at ir.onestopsystems.com. OSS regularly uses its website to disclose material and non-material information to investors, customers, employees and others interested in the company.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.

A replay of the call will be available after 8:00 p.m. Eastern time on the same day through May 27, 2021.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 9721579

About One Stop Systems

One Stop Systems, Inc. (OSS) designs and manufactures innovative AI Transportable™ edge computing modules and systems, including ruggedized servers, compute accelerators, expansion systems, flash storage arrays and Ion Accelerator™ SAN, NAS and data recording software for AI workflows. These products are used for AI data set capture, training, and large-scale inference in the defense, oil and gas, mining, autonomous vehicles and rugged entertainment applications.
  
OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for industrial OEMs and government customers. The company enables AI on the Fly® by bringing AI datacenter performance to ‘the edge’, especially on mobile platforms, and by addressing the entire AI workflow, from high-speed data acquisition to deep learning, training and inference. OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com.

Media Contact:

Katie Rivera
One Stop Systems, Inc.
Tel (760) 745-9883
Email contact

Investor Relations:

Ronald Both or Grant Stude
CMA
Tel (949) 432-7557
Email contact



Posted on

Media Advisory – Canadian Tire Corporation First Quarter Results and Annual Meeting of Shareholders

Canada NewsWire

TORONTO, April 29, 2021 /CNW/ – Canadian Tire Corporation, Limited (TSX: CTC) (TSX: CTC.A) will report its first quarter 2021 results and hold its Annual Meeting of Shareholders.

WHAT:

Q1 2021 Earnings Conference Call

WHEN:

Thursday, May 13, 2021 at 8:00 a.m. ET

CALL DETAILS:

1-800-952-5114 or 416-641-6104

Participant passcode: 3052170#

The conference call will be webcast live in its entirety at 8:00 a.m. ET at http://investors.canadiantire.ca and it will be archived for 12 months.

WHAT:


Annual Meeting of Shareholders

WHEN:

Thursday, May 13, 2021 at 10:00 a.m. ET

WHERE:

Virtual-only meeting via audio webcast and teleconference.

Online: http://web.lumiagm.com/490989159

Telephone:

English: 1-855-353-9183 / Access code: 22163#

French: 1-855-355-9283 / Access code: 18923#

Visit www.ctcagm.com for more information.

SOURCE CANADIAN TIRE CORPORATION, LIMITED

Posted on

Alterity Therapeutics Limited Appendix 4C – Q3 FY21 Quarterly Cash Flow Report

PR Newswire

Highlights:

  • Michael J. Fox Foundation grants Alterity $US495K for Parkinson’s disease research evaluation
  • Strengthening profile at investment, scientific and clinical conferences
  • Dr David Stamler appointed Chief Executive Officer
  • Cash balance as at 31 March 2021 of A$32.8M

MELBOURNE, Australia, April 29, 2021 /PRNewswire/ — Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2021 (Q3 FY21).

The company’s cash position was $32.8M with operational cash outflows of $5M, in line with company expectations and reflecting ongoing preparation for the Phase 2 clinical trial for Alterity’s lead drug candidate ATH434 in Multiple System Atrophy (MSA) patients.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates are included at item 6.1 of the Appendix 4C incorporates directors’ fees, consulting fees, remuneration and superannuation at commercial rates.

Operational Activities

During the quarter, Alterity continued to make important advances in its Phase 2 program.

Most of the company’s efforts were focused on the bioMUSE Natural History study in MSA patients being conducted at Vanderbilt University Medical Center. This study will provide important information and insights to inform patient selection and design of the Phase 2 trial, which is scheduled to begin later this year.  The study has now recruited 80% of the original target population and the company is evaluating the feasibility to expand enrollment.

The Michael J. Fox Foundation awarded Alterity US$495,000 to evaluate the pharmacologic profile of ATH434 to determine the optimal dose of the drug in future Parkinson’s disease clinical trials. It was the second grant the company has received from the Michael J. Fox Foundation for ATH434.

The profile of Alterity continues to strengthen with the company regularly invited to present at investor conferences and the leading clinical and scientific events around the world. In January and then again in March, Alterity CEO Dr David Stamler presented at life science and healthcare conferences hosted by HC Wainwright attended by institutional fund managers, HNW and other investors. Alterity also participated in the Biotech Showcase, a satellite event at the world’s largest healthcare conference hosted by JP Morgan.

In February, the company presented at the 7th Annual International Congress of Multiple System Atrophy, the pre-eminent conference for scientists and clinicians focused on MSA. Alterity’s presentation featured as part of the Congress’ poster presentation and provided further data on ATH434. The new results included data on blood pressure following change in body position which demonstrated that ATH434 does not lower blood pressure when people move to the standing position. This is an important safety finding considering impaired maintenance of blood pressure is a key issue with MSA.

In January, Alterity announced the appointment of Dr David Stamler to the role of Chief Executive Officer.  Dr Stamler is based in San Francisco and joined the Company in June 2017 as Chief Medical Officer and Senior Vice President Clinical Development.  Mr. Geoffrey Kempler, who founded the company in November 1997, has stepped down from the role of CEO and continues as Non-Executive Chairman. 

Authorisation & Additional information

This announcement was authorised by David Stamler, CEO of Alterity Therapeutics Limited.

About Alterity Therapeutics Limited and ATH434

Alterity’s lead candidate, ATH434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical Parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).

ATH434 has been granted Orphan designation for the treatment of MSA by the US FDA and the European Commission.

For further information please visit the Company’s web site at www.alteritytherapeutics.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, uncertainties relating to the impact of the novel coronavirus (COVID-19) pandemic on the company’s business, operations and employees, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to ATH434.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/alterity-therapeutics-limited-appendix-4c–q3-fy21-quarterly-cash-flow-report-301280196.html

SOURCE Alterity Therapeutics Limited